Salix Pharmaceuticals Ltd., of Raleigh, N.C., said the FDA considers the company's Aug. 29 resubmission of its supplemental new drug application for Xifaxan 550-mg tablets for the proposed indication of irritable bowel syndrome with diarrhea to be complete and assigned an action date of Feb. 28, 2015.